[HTML][HTML] Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: Current research and future perspective
Y Li, S Xiang, W Pan, J Wang, H Zhan, S Liu - Frontiers in Oncology, 2023 - frontiersin.org
Pancreatic cancer is one of the most malignant tumors with increased incidence rate. The
effect of surgery combined with chemoradiotherapy on survival of patients is unsatisfactory …
effect of surgery combined with chemoradiotherapy on survival of patients is unsatisfactory …
[HTML][HTML] Cellular immunotherapies for cancer
C Hayes - Irish Journal of Medical Science (1971-), 2021 - Springer
Cancer is a major burden on the healthcare system, and new therapies are needed.
Recently, the development of immunotherapies, which aim to boost or use the immune …
Recently, the development of immunotherapies, which aim to boost or use the immune …
[HTML][HTML] From bench to bedside a comprehensive review of pancreatic cancer immunotherapy
PR Kunk, TW Bauer, CL Slingluff… - Journal for immunotherapy …, 2016 - Springer
The incidence of pancreatic cancer has been increasing while its 5-year survival rate has
not changed in decades. In the era of personalized medicine, immunotherapy has emerged …
not changed in decades. In the era of personalized medicine, immunotherapy has emerged …
Opportunities and challenges in targeted therapy and immunotherapy for pancreatic cancer
D Cao, Q Song, J Li, Y Jiang, Z Wang… - Expert reviews in …, 2021 - cambridge.org
Pancreatic cancer is one of the most malignant tumours with a poor prognosis. In recent
years, the incidence of pancreatic cancer is on the rise. Traditional chemotherapy and …
years, the incidence of pancreatic cancer is on the rise. Traditional chemotherapy and …
[HTML][HTML] Advances in immunotherapeutics in pancreatic ductal adenocarcinoma
T Chouari, FS La Costa, N Merali, MD Jessel… - Cancers, 2023 - mdpi.com
Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is the most common type of
pancreatic cancer, responsible for the majority of cases and ranking seventh as a leading …
pancreatic cancer, responsible for the majority of cases and ranking seventh as a leading …
Combination treatment with comprehensive cryoablation and immunotherapy in metastatic pancreatic cancer
L Niu, J Chen, L He, M Liao, Y Yuan, J Zeng, J Li… - Pancreas, 2013 - journals.lww.com
Objective The aim of this study was to retrospectively assess the effect of comprehensive
cryosurgery (ablation of intrapancreatic and extrapancreatic tumors) plus immunotherapy in …
cryosurgery (ablation of intrapancreatic and extrapancreatic tumors) plus immunotherapy in …
Immunotherapy for pancreatic cancer: present and future
F Aroldi, A Zaniboni - Immunotherapy, 2017 - Future Medicine
Despite the identification of some efficient drugs for the treatment of metastatic pancreatic
cancer, this tumor remains one of the most lethal cancers and is characterized by a strong …
cancer, this tumor remains one of the most lethal cancers and is characterized by a strong …
Liver metastases of pancreatic cancer: role of repetitive transarterial chemoembolization (TACE) on tumor response and survival
A Azizi, NNN Naguib, E Mbalisike, P Farshid… - Pancreas, 2011 - journals.lww.com
Objective: To evaluate the effect of chemoembolization on pancreatic cancer liver
metastases. Method: Thirty-two patients with pancreatic cancer liver metastases …
metastases. Method: Thirty-two patients with pancreatic cancer liver metastases …
Dendritic cells in pancreatic cancer immunotherapy: Vaccines and combination immunotherapies
Despite significant advances over the past decades of research, pancreatic cancer (PC)
continues to have the worst 5-year survival of any malignancy. Dendritic cells (DCs) are the …
continues to have the worst 5-year survival of any malignancy. Dendritic cells (DCs) are the …
[HTML][HTML] Targeting dendritic cells in pancreatic ductal adenocarcinoma
A Deicher, R Andersson, B Tingstedt, G Lindell… - Cancer cell …, 2018 - Springer
Dendritic cells (DC) are an integral part of the tumor microenvironment. Pancreatic cancer is
characterized by reduced number and function of DCs, which impacts antigen presentation …
characterized by reduced number and function of DCs, which impacts antigen presentation …